share_log

ImmunoPrecise Antibodies Analyst Ratings

ImmunoPrecise Antibodies Analyst Ratings

免疫精準抗體分析師評級
Benzinga ·  2023/07/12 18:07
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
07/12/2023 199% HC Wainwright & Co. → $9 Reiterates Buy → Buy
07/11/2023 132.56% Benchmark → $7 Reiterates Speculative Buy → Speculative Buy
03/21/2023 132.56% Benchmark $12 → $7 Maintains Speculative Buy
03/17/2023 199% HC Wainwright & Co. → $9 Reiterates → Buy
12/02/2022 199% HC Wainwright & Co. → $9 Initiates Coverage On → Buy
10/25/2021 298.67% Benchmark → $12 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目標價格變動 評級變動 之前/當前的評級
07/12/2023 199% HC Wainwright & Co. → 9 美元 重申 購買 → 購買
07/11/2023 132.56% 基準 → 7 美元 重申 投機性買入 → 投機性買入
03/21/2023 132.56% 基準 12 美元 → 7 美元 維護 投機性買入
03/17/2023 199% HC Wainwright & Co. → 9 美元 重申 → 購買
12/02/2022 199% HC Wainwright & Co. → 9 美元 啓動覆蓋開啓 → 購買
2021 年 10 月 25 日 298.67% 基準 → 12 美元 啓動覆蓋開啓 → 購買

What is the target price for ImmunoPrecise Antibodies (IPA)?

免疫精準抗體 (IPA) 的目標價格是多少?

The latest price target for ImmunoPrecise Antibodies (NASDAQ: IPA) was reported by HC Wainwright & Co. on July 12, 2023. The analyst firm set a price target for $9.00 expecting IPA to rise to within 12 months (a possible 199.00% upside). 5 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年7月12日公佈了免疫精確抗體(納斯達克股票代碼:IPA)的最新目標股價。這家分析公司將目標股價定爲9.00美元,預計IPA將在12個月內升至9.00美元(可能上漲199.00%)。去年有5家分析公司公佈了評級。

What is the most recent analyst rating for ImmunoPrecise Antibodies (IPA)?

分析師對免疫精準抗體 (IPA) 的最新評級是多少?

The latest analyst rating for ImmunoPrecise Antibodies (NASDAQ: IPA) was provided by HC Wainwright & Co., and ImmunoPrecise Antibodies reiterated their buy rating.

分析師對ImmunoPrecise Antibities(納斯達克股票代碼:IPA)的最新評級由HC Wainwright & Co. 提供,ImmunoPrecise Antibitions重申

When is the next analyst rating going to be posted or updated for ImmunoPrecise Antibodies (IPA)?

免疫精準抗體 (IPA) 的下一個分析師評級何時公佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ImmunoPrecise Antibodies, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ImmunoPrecise Antibodies was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.

分析師在進行了廣泛的研究(包括瀏覽公開財務報表、與ImmunoPrecise Ambitions的高管和客戶交談以及聽取財報電話會議之後)得出了股票評級。大多數分析師每三個月進行一次評級,因此每家公司每年應該獲得4個評級。ImmunoPrecise 抗體的最新評級是在2023年7月12日提交的,因此您應該預計下一個評級將在2024年7月12日左右公佈。

Is the Analyst Rating ImmunoPrecise Antibodies (IPA) correct?

分析師對免疫精準抗體 (IPA) 的評級是否正確?

While ratings are subjective and will change, the latest ImmunoPrecise Antibodies (IPA) rating was a reiterated with a price target of $0.00 to $9.00. The current price ImmunoPrecise Antibodies (IPA) is trading at is $3.01, which is within the analyst's predicted range.

雖然評級是主觀的,將會發生變化,但最新的免疫精確抗體(IPA)評級得到了重申,目標股價爲0.00美元至9.00美元。ImmunoPrecise Antimentis(IPA)目前的交易價格爲3.01美元,在分析師的預測區間內。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論